Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Back
Share this video  

iwNHL 2019 | CAR-T vs bispecific antibodies for lymphoma

David Maloney, John Gribben and Laurie Sehn • 17 Sep 2019

John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, Laurie Sehn, MD, BC Cancer Agency, Prince George, BC, Canada, and David Maloney, MD, PhD, Fred Hutchinson Cancer Research Centre, Seattle, WA, discuss immunotherapies at the 17th International Workshop on Non-Hodgkin Lymphoma held in Boston, MA. They debate the success of bispecific antibodies compared with CAR T-cells, and highlight differences including cost, toxicity profiles and target antigen availability. In addition, they discuss the possibility of moving these new therapies forwards in the treatment pathway.